• Human iPSC Hepatobiliary Organoids: Study Insights

  2026-08-24

  Wu et al. developed a staged, three-dimensional system that generates hepatobiliary organoids from human induced pluripotent stem cells without exogenous cells or genetic manipulation. The organoids reproduced several hepatocyte and cholangiocyte functions, providing a defined platform for studying liver development, disease mechanisms, and drug responses.

• Stattic: Reading STAT3 Signaling Across Cell Contexts

  2026-08-23

  Stattic is a STAT3 inhibitor that can function as more than a cancer-biology reagent: it is a causal probe for distinguishing pathway activation from downstream phenotype. This article connects HNSCC studies with new evidence from lymphatic endothelial cells and translates that comparison into practical assay decisions.

• Cholecystokinin Octapeptide Ammonium: Assay Guide

  2026-08-22

  Cholecystokinin octapeptide ammonium is a sulfated CCK-8 research reagent for dissecting receptor-dependent brain–gut signaling. This guide connects salt-form handling with pathway-aware assays spanning ANP secretion, neuronal apoptosis, immune responses, and behavior.

• Sulfo-NHS-SS-Biotin: Practical Labeling Guide

  2026-08-22

  Sulfo-NHS-SS-Biotin provides water-compatible labeling of accessible primary amines for reversible affinity capture and detection. It is suitable for protein and cell-surface workflows, but should not be used in amine-containing reaction buffers or when downstream reduction could disrupt native disulfide bonds.

• Precision cDNA for HFpEF Gene Expression

  2026-08-21

  Translational cardiovascular studies depend on more than a measurable phenotype: they require an RNA-to-data workflow that preserves biological signal. Using TGFBR1-driven remodeling in HFpEF as a case study, this article explains how primer choice, reverse transcriptase performance, and validation strategy can strengthen mechanistic conclusions while positioning the HyperScript™ First-Strand cDNA Synthesis Kit for demanding gene expression workflows.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-08-20

  This FASEB Journal study developed a nonviral lipid nanoparticle system for delivering chemically modified CDKN1A/p21 mRNA directly into the bladder. The approach restored nuclear p21, restrained tumor-associated cell-cycle activity, and reduced orthotopic bladder tumor growth while limiting systemic exposure in mice.

• Sorafenib Workflows for Tumor and Angiogenesis Models

  2026-08-20

  Use BAY-43-9006 as a mechanistic benchmark for Raf/MEK/ERK signaling, VEGFR-driven angiogenesis, and tumor proliferation inhibition. This workflow-oriented guide connects cell assays, endothelial tube formation, hepatocellular carcinoma models, and xenograft study design while addressing solubility and interpretation challenges.

• NET Formation in CML and Differential TKI Effects

  2026-08-19

  The reference study shows that neutrophil extracellular trap formation is already elevated in treatment-naïve chronic myeloid leukemia and is differentially modified by tyrosine kinase inhibitors. Its combination of patient-derived neutrophils with a BCR-ABL1-engineered differentiation model identifies PAD4-linked NET biology as a potential mechanistic bridge between CML and treatment-associated vascular risk.

• Ibrutinib, CSK Inhibition, and Atrial Fibrillation

  2026-08-19

  This study identifies inhibition of C-terminal Src kinase, rather than Bruton tyrosine kinase blockade itself, as the principal mechanism linking ibrutinib to atrial fibrillation. By combining mouse electrophysiology, cardiac genetics, chemoproteomics, and pharmacovigilance analysis, the authors connect CSK loss with atrial remodeling, fibrosis, and inflammation. The findings illustrate why off-target kinase activity can shape both therapeutic safety and experimental interpretation.

• WY-14643 (Pirinixic Acid) in PPARα Research

  2026-08-18

  WY-14643 (Pirinixic Acid) gives researchers a practical PPARα activation tool for connecting lipid metabolism regulation with inflammatory and cell-death readouts. This workflow-focused guide shows how to use it in metabolic disorder research, endothelial inflammation assays, and mechanistic liver-injury studies while avoiding solubility and interpretation errors.

• Camptothecin and the Evolutionary Logic of DNA Damage

  2026-08-18

  Camptothecin is more than a benchmark topoisomerase I inhibitor: it is a controlled way to study how defined DNA lesions connect acute cell fate with longer-term genome adaptation. This thought-leadership perspective integrates its DNA damage and autophagy biology with a 2026 Cell study showing that prion-like protein self-assembly can tune mutagenesis, while distinguishing established evidence from translational hypotheses.

• BIBR 1532: Separating Telomerase and Telomere Stress

  2026-08-17

  BIBR 1532 is a selective telomerase inhibitor for distinguishing direct hTERT suppression from delayed telomere attrition and DNA-damage phenotypes. This article develops a two-clock assay strategy grounded in recent CF10–EdU findings and leukemia apoptosis data.

• CBD, FAAH, and Orofacial Inflammatory Pain

  2026-08-17

  This 2026 study shows that cannabidiol (CBD) can reduce both nociceptive and affective consequences of inflammatory pain through coordinated peripheral and central mechanisms involving FAAH, cannabinoid receptors, inflammatory mediators, and serotonin dynamics. Its multilevel design provides a useful framework for studying endocannabinoid signaling modulation while distinguishing sensory analgesia from anxiety-, depression-, and cognition-related outcomes.

• DAPT (GSI-IX): Reliable Cell Assay Design

  2026-08-16

  This scenario-based guide explains how DAPT (GSI-IX), SKU A8200, can help researchers design and interpret γ-secretase inhibition experiments across viability, proliferation, angiogenesis, and Notch signaling models. It connects product specifications with practical solvent handling, dose selection, controls, and evidence from a HUVEC and critical limb ischemia study.

• BIBP 3226 and the Adipose-Neural Axis

  2026-08-15

  A translational perspective on using BIBP 3226 trifluoroacetate to interrogate NPY Y1 signaling in epicardial adipose tissue-related arrhythmia research, with practical guidance for assay design, controls, and interpretation.

7773 records 1/519 page Next 12345 下5页 Last page